DJIA 17,751.39 121.12 0.69%
NASDAQ 5,111.73 22.53 0.44%
S&P 500 2,108.57 15.32 0.73%
market minute promo

Roche Holding Ltd. (ADR) (NASDAQOTH: RHHBY)



company name or ticker
Company Photos
(Click to zoom)

The Small-Cap Biotech Stock You Should Be Watching

Motley Fool experts offer up insight into three intriguing small-cap biotech stocks.

What are Penny Stocks?

Penny stocks have a popular allure, but the risks are bigger than you think. Here's why you should tread carefully.

Game-Changing News: Researchers May Have Discovered the Cause of Intestinal Cancer

Did researchers really uncover the mechanism behind intestinal cancer formation? Find out what game-changing news this latest study brings to light and how this could help drug developers plan their attack against intestinal cancers.

Why Exelixis Inc.'s Shares Soared Higher Today

Exelixis is rallying ahead of its presentation at a Wall Street healthcare conference tomorrow.

AstraZeneca plc Beefs Up Precision Medicine Arsenal

AstraZeneca upped the ante in precision medicine with the announcement of four new collaborations.

3 Medical Advancements You May Be Missing Out On

Motley Fool healthcare analysts highlight medical innovations that could prove to be profit friendly.

Fantastic News: A Revolutionary New Breast Cancer Drug Is on the Way

For the first time in more than 10 years a revolutionary new breast cancer treatment is ready to hit pharmacy shelves targeted at the most common type of breast cancer.

Which Biotech Stock Should Pfizer, Inc. Buy?

Motley Fool contributors offer up three potential acquisition targets for Pfizer.

In Case You Missed It, Researchers May Have Discovered a New Method to Treat Cancer

We know chemotherapy kills cancer cells, but it's also an indiscriminate killer of healthy cells. According to a new study released this past week, an entirely new treatment pathway could eliminate a significant portion of healthy cell death.

Why Exelixis, Inc. Shares Surged Higher By 30% in January

After a rough 2014 Exelixis shares surge in January after restructuring its distribution agreement for Cometriq and following an important announcement from a key drug development partner.
See More Articles...